5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Arterial O
Thromboembolic O
Events O
( O
ATEs O
) O
: O
Serious O
, O
sometimes O
fatal O
ATEs O
have O
been O
reported O
in O
clinical O
trials O
. O

Discontinue O
CYRAMZA O
for O
severe O
ATEs O
. O

( O
5.2 O
) O
* O
Hypertension O
: O
Monitor O
blood O
pressure O
and O
treat O
hypertension O
. O

Temporarily O
suspend O
CYRAMZA O
for O
severe O
hypertension O
. O

Discontinue O
CYRAMZA O
for O
hypertension O
that O
can O
not O
be O
medically O
controlled O
. O

( O
5.3 O
) O
* O
Infusion-Related O
Reactions O
: O
Monitor O
for O
signs O
and O
symptoms O
during O
infusion O
. O

( O
5.4 O
) O
* O
Impaired O
Wound O
Healing O
: O
Withhold O
CYRAMZA O
prior O
to O
surgery O
. O

( O
5.6 O
) O
* O
Clinical O
Deterioration O
in O
Patients O
with O
Cirrhosis O
: O
New O
onset O
or O
worsening O
encephalopathy O
, O
ascites O
, O
or O
hepatorenal O
syndrome O
can O
occur O
in O
patients O
with O
Child-Pugh O
B O
or O
C O
cirrhosis O
. O

( O
5.7 O
) O
* O
Reversible O
Posterior O
Leukoencephalopathy O
Syndrome O
: O
Discontinue O
CYRAMZA O
. O

( O
5.8 O
) O
* O
Proteinuria O
Including O
Nephrotic O
Syndrome O
: O
Monitor O
proteinuria O
. O

Interrupt O
CYRAMZA O
for O
urine O
protein O
levels O
> O
=2 O
g/24 O
hours O
. O

Permanently O
discontinue O
CYRAMZA O
for O
urine O
protein O
levels O
> O
3 O
g/24 O
hours O
or O
for O
nephrotic O
syndrome O
. O

( O
5.9 O
) O
* O
Thyroid O
Dysfunction O
: O
Monitor O
thyroid O
function O
during O
treatment O
with O
CYRAMZA O
. O

( O
5.10 O
) O
* O
Embryofetal O
Risk O
: O
Can O
cause O
fetal O
harm O
. O

( O
5.11 O
) O
5.1 O
Hemorrhage O
CYRAMZA O
increased O
the O
risk O
of O
hemorrhage B-OSE_Labeled_AE
and O
gastrointestinal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
including O
severe O
and O
sometimes O
fatal B-NonOSE_AE
hemorrhagic B-OSE_Labeled_AE
events I-OSE_Labeled_AE
. O

In O
Study O
1 O
, O
the O
incidence O
of O
severe O
bleeding B-OSE_Labeled_AE
was O
3.4 O
% O
for O
CYRAMZA O
and O
2.6 O
% O
for O
placebo O
. O

In O
Study O
2 O
, O
the O
incidence O
of O
severe O
bleeding B-OSE_Labeled_AE
was O
4.3 O
% O
for O
CYRAMZA O
plus O
paclitaxel O
and O
2.4 O
% O
for O
placebo O
plus O
paclitaxel O
. O

Patients O
with O
gastric B-Not_AE_Candidate
cancer I-Not_AE_Candidate
receiving O
nonsteroidal O
anti-inflammatory O
drugs O
( O
NSAIDs O
) O
were O
excluded O
from O
enrollment O
in O
Studies O
1 O
and O
2 O
; O
therefore O
, O
the O
risk O
of O
gastric B-NonOSE_AE
hemorrhage I-NonOSE_AE
in O
CYRAMZA-treated O
patients O
with O
gastric B-Not_AE_Candidate
tumors I-Not_AE_Candidate
receiving O
NSAIDs O
is O
unknown O
. O

In O
Study O
3 O
, O
the O
incidence O
of O
severe O
bleeding B-OSE_Labeled_AE
was O
2.4 O
% O
for O
CYRAMZA O
plus O
docetaxel O
and O
2.3 O
% O
for O
placebo O
plus O
docetaxel O
. O

Patients O
with O
NSCLC B-Not_AE_Candidate
receiving O
therapeutic O
anticoagulation O
or O
chronic O
therapy O
with O
NSAIDS O
or O
other O
anti-platelet O
therapy O
other O
than O
once O
daily O
aspirin O
or O
with O
radiographic O
evidence O
of O
major B-Not_AE_Candidate
airway I-Not_AE_Candidate
or O
blood O
vessel O
invasion I-Not_AE_Candidate
or O
intratumor B-Not_AE_Candidate
cavitation I-Not_AE_Candidate
were O
excluded O
from O
Study O
3 O
; O
therefore O
the O
risk O
of O
pulmonary B-NonOSE_AE
hemorrhage I-NonOSE_AE
in O
these O
groups O
of O
patients O
is O
unknown O
. O

In O
Study O
4 O
, O
the O
incidence O
of O
severe O
bleeding B-OSE_Labeled_AE
was O
2.5 O
% O
for O
CYRAMZA O
plus O
FOLFIRI O
and O
1.7 O
% O
for O
placebo O
plus O
FOLFIRI O
. O

Permanently O
discontinue O
CYRAMZA O
in O
patients O
who O
experience O
severe O
bleeding B-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

5.2 O
Arterial O
Thromboembolic O
Events O
Serious O
, O
sometimes O
fatal B-NonOSE_AE
, O
arterial B-OSE_Labeled_AE
thromboembolic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
( I-OSE_Labeled_AE
ATEs I-OSE_Labeled_AE
) I-OSE_Labeled_AE
including O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
, O
cardiac B-OSE_Labeled_AE
arrest I-OSE_Labeled_AE
, O
cerebrovascular B-OSE_Labeled_AE
accident I-OSE_Labeled_AE
, O
and O
cerebral B-OSE_Labeled_AE
ischemia I-OSE_Labeled_AE
occurred O
in O
clinical O
trials O
including O
1.7 O
% O
of O
236 O
patients O
who O
received O
CYRAMZA O
as O
a O
single O
agent O
for O
gastric B-Not_AE_Candidate
cancer I-Not_AE_Candidate
in O
Study O
1 O
. O

Permanently O
discontinue O
CYRAMZA O
in O
patients O
who O
experience O
a O
severe O
ATE B-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

5.3 O
Hypertension O
An O
increased O
incidence O
of O
severe O
hypertension B-OSE_Labeled_AE
occurred O
in O
patients O
receiving O
CYRAMZA O
as O
a O
single O
agent O
( O
8 O
% O
) O
as O
compared O
to O
placebo O
( O
3 O
% O
) O
, O
in O
patients O
receiving O
CYRAMZA O
plus O
paclitaxel O
( O
15 O
% O
) O
as O
compared O
to O
placebo O
plus O
paclitaxel O
( O
3 O
% O
) O
, O
in O
patients O
receiving O
CYRAMZA O
plus O
docetaxel O
( O
6 O
% O
) O
as O
compared O
to O
placebo O
plus O
docetaxel O
( O
2 O
% O
) O
, O
and O
in O
patients O
receiving O
CYRAMZA O
plus O
FOLFIRI O
( O
11 O
% O
) O
as O
compared O
to O
placebo O
plus O
FOLFIRI O
( O
3 O
% O
) O
. O

Control O
hypertension B-Not_AE_Candidate
prior O
to O
initiating O
treatment O
with O
CYRAMZA O
. O

Monitor O
blood O
pressure O
every O
two O
weeks O
or O
more O
frequently O
as O
indicated O
during O
treatment O
. O

Temporarily O
suspend O
CYRAMZA O
for O
severe O
hypertension B-NonOSE_AE
until O
medically O
controlled O
. O

Permanently O
discontinue O
CYRAMZA O
if O
medically O
significant O
hypertension B-NonOSE_AE
can O
not O
be O
controlled O
with O
antihypertensive B-NonOSE_AE
therapy I-NonOSE_AE
or O
in O
patients O
with O
hypertensive B-NonOSE_AE
crisis I-NonOSE_AE
or O
hypertensive B-NonOSE_AE
encephalopathy I-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

5.4 O
Infusion B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Related I-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
Prior O
to O
the O
institution O
of O
premedication O
recommendations O
across O
clinical O
trials O
of O
CYRAMZA O
, O
IRRs B-OSE_Labeled_AE
occurred O
in O
6 O
out O
of O
37 O
patients O
( O
16 O
% O
) O
, O
including O
two O
severe O
events O
. O

The O
majority O
of O
IRRs B-OSE_Labeled_AE
across O
trials O
occurred O
during O
or O
following O
a O
first O
or O
second O
CYRAMZA O
infusion O
. O

Symptoms O
of O
IRRs B-NonOSE_AE
included O
rigors B-NonOSE_AE
/ O
tremors B-NonOSE_AE
, O
back B-NonOSE_AE
pain I-NonOSE_AE
/spasms O
, O
chest B-NonOSE_AE
pain I-NonOSE_AE
and/or O
tightness O
, O
chills B-NonOSE_AE
, O
flushing B-NonOSE_AE
, O
dyspnea B-NonOSE_AE
, O
wheezing B-NonOSE_AE
, O
hypoxia B-NonOSE_AE
, O
and O
paresthesia B-NonOSE_AE
. O

In O
severe O
cases O
, O
symptoms O
included O
bronchospasm B-NonOSE_AE
, O
supraventricular B-NonOSE_AE
tachycardia I-NonOSE_AE
, O
and O
hypotension B-NonOSE_AE
. O

Monitor O
patients O
during O
the O
infusion O
for O
signs O
and O
symptoms O
of O
IRRs B-NonOSE_AE
in O
a O
setting O
with O
available O
resuscitation O
equipment O
. O

Immediately O
and O
permanently O
discontinue O
CYRAMZA O
for O
Grade O
3 O
or O
4 O
IRRs B-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

5.5 O
Gastrointestinal O
Perforations O
CYRAMZA O
is O
an O
antiangiogenic O
therapy O
that O
can O
increase O
the O
risk O
of O
gastrointestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
, O
a O
potentially O
fatal O
event O
. O

Four O
of O
570 O
patients O
( O
0.7 O
% O
) O
who O
received O
CYRAMZA O
as O
a O
single O
agent O
in O
clinical O
trials O
experienced O
gastrointestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
. O

In O
Study O
2 O
, O
the O
incidence O
of O
gastrointestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
was O
also O
increased O
in O
patients O
that O
received O
CYRAMZA O
plus O
paclitaxel O
( O
1.2 O
% O
) O
as O
compared O
to O
patients O
receiving O
placebo O
plus O
paclitaxel O
( O
0.3 O
% O
) O
. O

In O
Study O
3 O
, O
the O
incidence O
of O
gastrointestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
was O
1 O
% O
for O
CYRAMZA O
plus O
docetaxel O
and O
0.3 O
% O
for O
placebo O
plus O
docetaxel O
. O

In O
Study O
4 O
, O
the O
incidence O
of O
gastrointestinal B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
was O
1.7 O
% O
for O
CYRAMZA O
plus O
FOLFIRI O
and O
0.6 O
% O
for O
placebo O
plus O
FOLFIRI O
. O

Permanently O
discontinue O
CYRAMZA O
in O
patients O
who O
experience O
a O
gastrointestinal B-NonOSE_AE
perforation I-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

5.6 O
Impaired O
Wound O
Healing O
Impaired B-OSE_Labeled_AE
wound I-OSE_Labeled_AE
healing I-OSE_Labeled_AE
can O
occur O
with O
antibodies O
inhibiting O
the O
VEGF O
pathway O
. O

CYRAMZA O
has O
not O
been O
studied O
in O
patients O
with O
serious O
or O
non-healing O
wounds O
. O

CYRAMZA O
, O
an O
antiangiogenic O
therapy O
, O
has O
the O
potential O
to O
adversely B-NonOSE_AE
affect I-NonOSE_AE
wound I-NonOSE_AE
healing I-NonOSE_AE
. O

Discontinue O
CYRAMZA O
therapy O
in O
patients O
with O
impaired B-NonOSE_AE
wound I-NonOSE_AE
healing I-NonOSE_AE
. O

Withhold O
CYRAMZA O
prior O
to O
surgery O
. O

Resume O
following O
the O
surgical O
intervention O
based O
on O
clinical O
judgment O
of O
adequate O
wound O
healing O
. O

If O
a O
patient O
develops O
wound B-NonOSE_AE
healing I-NonOSE_AE
complications I-NonOSE_AE
during O
therapy O
, O
discontinue O
CYRAMZA O
until O
the O
wound O
is O
fully O
healed O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

5.7 O
Clinical O
Deterioration O
in O
Patients O
with O
Child-Pugh O
B O
or O
C O
Cirrhosis O
Clinical O
deterioration B-OSE_Labeled_AE
, O
manifested O
by O
new O
onset O
or O
worsening O
encephalopathy O
, O
ascites O
, O
or O
hepatorenal O
syndrome O
was O
reported O
in O
patients O
with O
Child I-OSE_Lab
eled B-NonOSE_AE
_ I-NonOSE_AE
AE I-NonOSE_AE
- I-NonOSE_AE
  I-NonOSE_AE
I I-NonOSE_AE
- I-NonOSE_AE
O I-NonOSE_AE
SE O
_ B-NonOSE_AE
Labele I-NonOSE_AE
d_AE O
Pug B-NonOSE_AE
h I-NonOSE_AE
  I-NonOSE_AE
I I-NonOSE_AE
-OS I-NonOSE_AE
E I-NonOSE_AE
_Labele I-NonOSE_AE
d I-NonOSE_AE
_AE O
B I-OSE_Labeled_AE
or O
C O
cirrhosis I-OSE_Labeled_AE
who O
received O
single-agent O
CYRAMZA O
. O

Use O
CYRAMZA O
in O
patients O
with O
Child B-Not_AE_Candidate
- I-Not_AE_Candidate
Pugh I-Not_AE_Candidate
B I-Not_AE_Candidate
or O
C O
cirrhosis I-Not_AE_Candidate
only O
if O
the O
potential O
benefits O
of O
treatment O
are O
judged O
to O
outweigh O
the O
risks O
of O
clinical O
deterioration O
. O

5.8 O
Reversible O
Posterior O
Leukoencephalopathy O
Syndrome O
Reversible B-OSE_Labeled_AE
Posterior I-OSE_Labeled_AE
Leukoencephalopathy I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
RPLS I-OSE_Labeled_AE
) O
has O
been O
reported O
with O
a O
rate O
of O
< O
0.1 O
% O
in O
clinical O
studies O
with O
CYRAMZA O
. O

Confirm O
the O
diagnosis O
of O
RPLS B-NonOSE_AE
with O
MRI O
and O
discontinue O
CYRAMZA O
in O
patients O
who O
develop O
RPLS B-NonOSE_AE
. O

Symptoms O
may O
resolve O
or O
improve O
within O
days O
, O
although O
some O
patients O
with O
RPLS B-NonOSE_AE
can O
experience O
ongoing O
neurologic B-NonOSE_AE
sequelae I-NonOSE_AE
or O
death B-NonOSE_AE
. O

5.9 O
Proteinuria O
Including O
Nephrotic O
Syndrome O
In O
Study O
4 O
, O
severe O
proteinuria B-OSE_Labeled_AE
occurred O
more O
frequently O
in O
patients O
treated O
with O
CYRAMZA O
plus O
FOLFIRI O
compared O
to O
patients O
receiving O
placebo O
plus O
FOLFIRI O
. O

Severe O
proteinuria B-OSE_Labeled_AE
was O
reported O
in O
3 O
% O
of O
patients O
treated O
with O
CYRAMZA O
plus O
FOLFIRI O
( O
including O
3 O
cases O
[ O
0.6 O
% O
] O
of O
nephrotic B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
) O
compared O
to O
0.2 O
% O
of O
patients O
treated O
with O
placebo O
plus O
FOLFIRI O
. O

Monitor O
proteinuria B-NonOSE_AE
by O
urine O
dipstick O
and/or O
urinary O
protein O
creatinine O
ratio O
for O
the O
development O
of O
worsening O
of O
proteinuria B-NonOSE_AE
during O
CYRAMZA O
therapy O
. O

Withhold O
CYRAMZA O
for O
urine O
protein O
levels O
that O
are O
2 O
or O
more O
grams O
over O
24 O
hours O
. O

Reinitiate O
CYRAMZA O
at O
a O
reduced O
dose O
once O
the O
urine O
protein O
level O
returns O
to O
less O
than O
2 O
grams O
over O
24 O
hours O
. O

Permanently O
discontinue O
CYRAMZA O
for O
urine O
protein O
levels O
greater O
than O
3 O
grams O
over O
24 O
hours O
or O
in O
the O
setting O
of O
nephrotic B-NonOSE_AE
syndrome I-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

5.10 O
Thyroid O
Dysfunction O
Monitor O
thyroid O
function O
during O
treatment O
with O
CYRAMZA O
. O

In O
Study O
4 O
, O
the O
incidence O
of O
hypothyroidism B-OSE_Labeled_AE
reported O
as O
an O
adverse O
event O
was O
2.6 O
% O
in O
the O
CYRAMZA O
plus O
FOLFIRI O
treated O
patients O
and O
0.9 O
% O
in O
the O
placebo O
plus O
FOLFIRI O
treated O
patients O
. O

5.11 O
Embryofetal B-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
Based O
on O
its O
mechanism O
of O
action O
, O
CYRAMZA O
can O
cause O
fetal B-OSE_Labeled_AE
harm I-OSE_Labeled_AE
when O
administered O
to O
pregnant B-Not_AE_Candidate
women O
. O

Animal O
models O
link O
angiogenesis O
, O
VEGF O
and O
VEGF O
Receptor O
2 O
( O
VEGFR2 O
) O
to O
critical O
aspects O
of O
female O
reproduction O
, O
embryofetal O
development O
, O
and O
postnatal O
development O
. O

Advise O
pregnant B-Not_AE_Candidate
women O
of O
the O
potential O
risk B-OSE_Labeled_AE
to I-OSE_Labeled_AE
a I-OSE_Labeled_AE
fetus I-OSE_Labeled_AE
. O

Advise O
females O
of O
reproductive O
potential O
to O
use O
effective O
contraception O
during O
treatment O
with O
CYRAMZA O
and O
for O
at O
3 O
least O
months O
after O
the O
last O
dose O
of O
CYRAMZA O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.1 O
, O
8.3 O
) O
] O
. O

